The impact of age and gender on the presentation and prognosis of medullary thyroid cancer - an Israeli multicenter study

2017 ◽  
Author(s):  
Orit Twito ◽  
Simona Grozinsky-Glasberg ◽  
Carlos Benbassat ◽  
Sigal Llevy ◽  
Gideon Bachar ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Multicenter Study ◽  
Medullary Thyroid Cancer ◽  
Age And Gender ◽  
Medullary Thyroid ◽  
And Gender ◽  
The Impact

scholarly journals The Impact of Age and Gender on Papillary Thyroid Cancer Survival

2012 ◽  
Vol 97 (6) ◽  
pp. E878-E887 ◽  
Author(s):  
J. Jonklaas ◽  
G. Nogueras-Gonzalez ◽  
M. Munsell ◽  
D. Litofsky ◽  
K. B. Ain ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Cancer Survival ◽  
Papillary Thyroid ◽  
Age And Gender ◽  
And Gender ◽  
The Impact

scholarly journals The impact of family history on non-medullary thyroid cancer

2016 ◽  
Vol 42 (10) ◽  
pp. 1455-1463 ◽  
Author(s):  
I.J. Nixon ◽  
C. Suárez ◽  
R. Simo ◽  
A. Sanabria ◽  
P. Angelos ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Family History ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid ◽  
The Impact

scholarly journals Medullary thyroid cancer (MTC): descriptive analysis and prognostic factors in a multicenter study

2016 ◽  
Author(s):  
Victoria Alcazar ◽  
Concepcion Blanco ◽  
Cristina Alvarez-Escola ◽  
Guadalupe Guijarro ◽  
Javier Estrada ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Multicenter Study ◽  
Medullary Thyroid Cancer ◽  
Descriptive Analysis ◽  
Medullary Thyroid

scholarly journals Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model

2019 ◽  
Vol 23 (8) ◽  
pp. 1-144 ◽  
Author(s):  
Paul Tappenden ◽  
Christopher Carroll ◽  
Jean Hamilton ◽  
Eva Kaltenthaler ◽  
Ruth Wong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Locally Advanced ◽  
Clinical Effectiveness ◽  
Primary Research ◽  
Open Label ◽  
Medullary Thyroid ◽  
The Impact ◽  
The Eu

BackgroundMedullary thyroid cancer (MTC) is a rare form of cancer that affects patients’ health-related quality of life (HRQoL) and survival. Cabozantinib (Cometriq®; Ipsen, Paris, France) and vandetanib (Caprelsa®; Sanofi Genzyme, Cambridge, MA, USA) are currently the treatment modality of choice for treating unresectable progressive and symptomatic MTC.Objectives(1) To evaluate the clinical effectiveness and safety of cabozantinib and vandetanib. (2) To estimate the incremental cost-effectiveness of cabozantinib and vandetanib versus each other and best supportive care. (3) To identify key areas for primary research. (4) To estimate the overall cost of these treatments in England.Data sourcesPeer-reviewed publications (searched from inception to November 2016), European Public Assessment Reports and manufacturers’ submissions.Review methodsA systematic review [including a network meta-analysis (NMA)] was conducted to evaluate the clinical effectiveness and safety of cabozantinib and vandetanib. The economic analysis included a review of existing analyses and the development of a de novo model.ResultsThe systematic review identified two placebo-controlled trials. The Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM) trial evaluated the efficacy and safety of cabozantinib in patients with unresectable locally advanced, metastatic and progressive MTC. The ZETA trial evaluated the efficacy and safety of vandetanib in patients with unresectable locally advanced or metastatic MTC. Both drugs significantly improved progression-free survival (PFS) more than the placebo (p < 0.001). The NMA suggested that, within the symptomatic and progressive MTC population, the effects on PFS were similar (vandetanib vs. cabozantinib: hazard ratio 1.14, 95% credible interval 0.41 to 3.09). Neither trial demonstrated a significant overall survival benefit for cabozantinib or vandetanib versus placebo, although data from ZETA were subject to potential confounding. Both cabozantinib and vandetanib demonstrated significantly better objective response rates and calcitonin (CTN) and carcinoembryonic antigen (CEA) response rates than placebo. Both cabozantinib and vandetanib produced frequent adverse events, often leading to dose interruption or reduction. The assessment group model indicates that, within the EU-label population (symptomatic and progressive MTC), the incremental cost-effectiveness ratios (ICERs) for cabozantinib and vandetanib are > £138,000 per quality-adjusted life-year (QALY) gained. Within the restricted EU-label population (symptomatic and progressive MTC with CEA/CTN doubling times of ≤ 24 months), the ICER for vandetanib is expected to be > £66,000 per QALY gained. The maximum annual budget impact within the symptomatic and progressive population is estimated to be ≈£2.35M for cabozantinib and ≈£5.53M for vandetanib. The costs of vandetanib in the restricted EU-label population are expected to be lower.LimitationsThe intention-to-treat populations of the EXAM and ZETA trials are notably different. The analyses of ZETA subgroups may be subject to confounding as a result of differences in baseline characteristics and open-label vandetanib use. Attempts to statistically adjust for treatment switching were unsuccessful. No HRQoL evidence was identified for the MTC population.ConclusionsThe identified trials suggest that cabozantinib and vandetanib improve PFS more than the placebo; however, significant OS benefits were not demonstrated. The economic analyses indicate that within the EU-label population, the ICERs for cabozantinib and vandetanib are > £138,000 per QALY gained. Within the restricted EU-label population, the ICER for vandetanib is expected to be > £66,000 per QALY gained.Future research priorities(1) Primary research assessing the long-term effectiveness of cabozantinib and vandetanib within relevant subgroups. (2) Reanalyses of the ZETA trial to investigate the impact of adjusting for open-label vandetanib use using appropriate statistical methods. (3) Studies assessing the impact of MTC on HRQoL.Study registrationThis study is registered as PROSPERO CRD42016050403.FundingThe National Institute for Health Research Health Technology Assessment programme.

scholarly journals The Impact of the Extent of Surgery on the Long-Term Outcomes of Patients with Low-Risk Differentiated Non-Medullary Thyroid Cancer: A Systematic Meta-Analysis

2020 ◽  
Vol 9 (7) ◽  
pp. 2316 ◽  
Author(s):  
Andreea Bojoga ◽  
Anna Koot ◽  
Johannes Bonenkamp ◽  
Johannes de Wilt ◽  
Joanna IntHout ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Low Risk ◽  
American Thyroid Association ◽  
Medullary Thyroid ◽  
Thyroid Lobectomy ◽  
Extent Of Surgery ◽  
The Impact

Recently, the management of patients with low-risk differentiated non-medullary thyroid cancer (DTC), including papillary and follicular thyroid carcinoma subtypes, has been critically appraised, questioning whether these patients might be overtreated without a clear clinical benefit. The American Thyroid Association (ATA) guideline suggests that thyroid lobectomy (TL) could be a safe alternative for total thyroidectomy (TT) in patients with DTC up to 4 cm limited to the thyroid, without metastases. We conducted a meta-analysis to assess the clinical outcomes in patients with low-risk DTC based on the extent of surgery. The risk ratio (RR) of recurrence rate, overall survival (OS), disease-free survival (DFS) and disease specific survival (DSS) were estimated. In total 16 studies with 175,430 patients met the inclusion criteria. Overall, low recurrence rates were observed for both TL and TT groups (7 vs. 7%, RR 1.10, 95% CI 0.61–1.96, I2 = 72%), and no statistically significant differences for OS (TL 94.1 vs. TT 94.4%, RR 0.99, CI 0.99–1.00, I2 = 53%), DFS (TL 87 vs. TT 91%, RR 0.96, CI 0.89–1.03, I2 = 85%), and DSS (TL 97.2 vs. TT 95.4%, RR 1.01, CI 1.00–1.01, I2 = 74%). The high degree of heterogeneity of the studies is a notable limitation. Conservative management and appropriate follow-up instead of bilateral surgery would be justifiable in selected patients. These findings highlight the importance of shared-decision making in the management of patients with small, low-risk DTC.

Medullary Thyroid Cancer and the Impact of Genetic Testing

2006 ◽  
Vol 10 (5) ◽  
pp. 571-575 ◽  
Author(s):  
Erika L. Keatts ◽  
Joanne Itano
Keyword(s):  
Thyroid Cancer ◽  
Genetic Testing ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid ◽  
The Impact

Abstract #1101 The Value of Calcitonin Calcium Stimulation Test Levels as Predictors of Medullary Thyroid Cancer.

2018 ◽  
Vol 24 ◽  
pp. 273-274
Author(s):  
Corin Badiu ◽  
Mara Baet ◽  
Ruxandra Dobrescu ◽  
Andra Caragheorgheopol ◽  
Corneci Cristina
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Stimulation Test ◽  
Medullary Thyroid ◽  
Calcium Stimulation

Immunoscintigraphy in Medullary Thyroid Cancer Using an 123I- or 111ln-Labelled Monoclonal Anti-CEA Antibody Fragment

1986 ◽  
Vol 25 (06) ◽  
pp. 227-231 ◽  
Author(s):  
Chr. Eilles ◽  
W. Spiegel ◽  
W. Becker ◽  
W. Börner ◽  
Chr. Reiners
Keyword(s):  
Bone Marrow ◽  
Thyroid Cancer ◽  
Potassium Iodide ◽  
Medullary Thyroid Cancer ◽  
Elevated Serum ◽  
Antibody Fragment ◽  
Special Importance ◽  
Medullary Thyroid ◽  
Medullary Cancer ◽  
Serum Cea

The monoclonal anti-CEA F(ab’)2 fragment MAb BW 431/31, labelled with 123I or111 In, was used for immunoscintigraphy (IS) in 9 patients with medullary cancer of the thyroid (CCC). The results of 11 studies lead to the following conclusions: 1) When using radioiodine as a label for MAb in IS, potassium iodide is absolutely necessary to block the thyroid which is of special importance in patients with thyroid cancer; 2) Preinjection of “cold” MAb reduces the relatively high unspecific uptake (especially in bone marrow) of MAb BW 431/31, which is of special importance for the antibody labelled with 111 In; 3) IS with MAb BW 413/31 in patients with CCC and elevated serum CEA is positive only in cases with large secondaries; and 4) In patients with CCC and several manifestations of secondaries, only a single (large) metastasis may be apparent.

NTRK3 receptor expression is strictly associated with medullary thyroid cancer RET mutation status

2014 ◽  
Author(s):  
Malgorzata Oczko-Wojciechowska ◽  
Michal Swierniak ◽  
Malgorzata Kowalska ◽  
Agnieszka Pawlaczek ◽  
Monika Kowal ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Receptor Expression ◽  
Mutation Status ◽  
Medullary Thyroid ◽  
Ret Mutation
Sign in / Sign up

Export Citation Format

Share Document